Inherited retinal diseases treatment sales will strengthen through 2036, anchored by gene therapy treatment at a 57.6% share in 2026 as the leading treatment type segment. The market was valued at USD 12.6 billion in 2025 and is expected to reach USD 30.91 billion by 2036, creating an incremental opportunity of USD 17.24 billion.